Urinary Tract Infections and Antibiotic Susceptibility Patterns in Sheki, Azerbaijan

Yıl 2026, Cilt: 11 Sayı: 1, 1 - 8, 14.03.2026

Nazile Behbudova , Lale Kazimova , Keramettin Yanık

https://doi.org/10.58854/jicm.1831038

https://izlik.org/JA23NZ44YN

Öz

Aim: To describe the etiologic distribution of culture-confirmed urinary tract infections (UTIs) in the Sheki region and summarize organism-specific susceptibility patterns under EUCAST interpretation. Methods: We retrospectively analyzed urine specimens processed in a single microbiology laboratory between September 2024 and April 2025. Specimens were cultured on blood agar and EMB agar and incubated aerobically at 37°C for 24–48 hours. Isolates were identified using the API system, and antimicrobial susceptibility has been determined by disk diffusion per EUCAST; duplicate and contaminated submissions were excluded. Analyses were descriptive only. Results: Significant growth was found in 42 of 85 applications (49.4%) .The mostcammon causative was Echerichia coli (20/41; 47.6%)and four strains(20%)were found to be extended-spectrum beta lactamase(ESBL)-pozitive.ESBL-pozitive aminoglycoside resistance and cefosporin resistance were observed in Klebsiella oxytoca and Klebsiella pneumaniae strains.Xinolone persistence was most common in Citrobacter spp.Aminoglycoside resistance was observed in Echerichia coli,Klebsiella spp and Raoultella spp..No antibiotic resistance was detected in Qram-positive bacteria.Conclusion: Local susceptibility data support narrow-spectrum empiric regimens for uncomplicated UTIs (notably nitrofurantoin and fosfomycin), while fluoroquinolones and broad-spectrum β-lactams should be reserved given resistance and ecological considerations. Limitations include the single-center, retrospective design, small numbers for certain taxa, and absence of adjusted analyses; larger, prospective studies are warranted.

Anahtar Kelimeler

antimicrobial resistance; , Escherichia coli , EUCAST; , nitrofurantoin

Etik Beyan

NO.All patient date were anonymized

Destekleyen Kurum

NO

Proje Numarası

No

Teşekkür

I sincerely thank all who supported this study.

Şeki, Azerbaycan’da İdrar Yolu Enfeksiyonları ve Antibiyotik Duyarlılığı

https://izlik.org/JA23NZ44YN

Öz

Amaç: Şəki bölgesinde kültürle doğrulanmış idrar yolu infeksiyonlarının (İYE) etiyolojik dağılımını ve EUCAST yorumuna göre organizmaya özgü duyarlılık paternlerini tanımlamak. Yöntem: Eylül 2024–Nisan 2025 arasında tek merkezli bir mikrobiyoloji laboratuvarında işlenen idrar örnekleri retrospektif olarak incelendi. Örnekler kanlı agar ve EMB agara ekildi, 37°C’de 24–48 saat aerob inkübe edildi. İzolatlar API sistemi ile tanımlandı; antimikrobiyal duyarlılık EUCAST’a göre disk difüzyon yöntemiyle belirlendi; yinelenen ve kontamine örnekler dışlandı. Analizler yalnız betimleyicidir. Bulgular: 85 başvurunun 42’inde (%49.4) anlamlı üreme saptandı. En sık etken Escherichia coli olup (%47,6),dört suş (20%)genişlenmiş spektrumlu beta-laktamaz (ESBL)pozitiv bulunmuştur.Klebsiella pneumaniae ve Klebsiella oxytoca suşlarında ESBL pozitivliyi,aminoqlikozit direncı ve sefolosporin direncisaptanmıştır.Xinolon devamlılığı en çok Citrobakter spp.de,Aminoglikozit direnci ise Echerichia coli,Klebsiella spp ve Raoultella spp.suşlarında görülmüşdür.Qram pozitiv bakterilerde ise antibiyotik direnci saptanmamıştır.So nuç: Yerel duyarlılık verileri, komplike olmayan İYE’de dar spektrumlu ampirik rejimleri (özellikle nitrofurantoin ve fosfomisin) desteklemekte; florokinolonlar ve geniş spektrumlu β‑laktamlar direnç ve ekolojik etkiler nedeniyle seçici/ sınırlı kullanılmalıdır. Sınırlılıklar arasında tek merkezli retrospektif tasarım, bazı taksonlarda küçük örneklem ve ayarlı analizlerin olmaması yer almakta; daha büyük, prospektif çalışmalar gereklidir.

Anahtar Kelimeler

Antibiyotik Direnci , Escherichia coli , ESBL , Klebsiella spp.

Etik Beyan

bütün hasta malumatları anonim saklanılmıştır.Etik beyan yoktur.

Destekleyen Kurum

Yoktur

Proje Numarası

No

Teşekkür

Her kese teşekkür ederim.

Kaynakça

• Antwi-Boasiako MN, Ayensu F, Awuah A, Mutala A-H, Boampong K, Badu K. Prevalence, Diagnostic Accuracy, and Antimicrobial Resistance Patterns of Uropathogens in Urinary Tract Infections at a Health Facility in Kumasi, Ghana. Mol Biol Rep. 2025;PMID:40862549. doi:10.1002/mbo3.70028
• Baimakhanova B, Sadanov A, Trenozhnikova L, Balgimbaeva A, Baimakhanova G, Orasymbet S, et al. Understanding the Burden and Management of Urinary Tract Infections in Women. Diseases. 2025;13(2):59. doi: 10.3390/ diseases13020059
• Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012 Mar 15;366(11):1028-1037. doi:10.1056/ NEJMcp1104429. PMID:22417256
• Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: A worldwide report. Front Public Health. 2022;10:888205. doi:10.3389/ fpubh.2022.888205. PMID:35968451
• Kallen, A.J.; Welch, H.G.; Sirovich, B.E. Current antibiotic therapy for isolated urinary tract infections in women. Arch. Intern. Med. 2006, 166, 635–639
• Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao p, Wool E, et al. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629–655. doi: 10.1016/S0140-6736(21)02724-0
• McEwen SA, Collignon PJ. 2018. Antimicrobial resistance: a one health perspective. Microbiol Spectr 6. doi: 10.1128/microbiolspec.arba 0009-2017
• Mareș C, Petca R-C, Popescu R-I, Petca A, Geavlete BF, Jinga V et al. Uropathogens’ Antibiotic Resistance Evolution in a Female Population: A Sequential Multi-Year Comparative Analysis. Antibiotics (Basel). 2023 May 23;12(6):948. doi:10.3390/ antibiotics12060948. PMID: PMCID: PMC10294854. 37370266;
• Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology, 13(5), 269–284. https:// doi.org/10.1038/nrmicro3432
• Bono, M.J., & Leslie, S.W. Uncomplicated urinary tract infections [Electronic version]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Feb 21. Accessed September 17, 2025, from https://www.ncbi. nlm.nih.gov/books/NBK470195/
• Czajkowski K, Broś-Konopielko M, Teliga Czajkowska J. Urinary tract infection in women. Prz Menopauzalny. 2021 Apr 21;20(1):40 47. doi:10.5114/pm.2021.105382. PMID: 33935619; PMCID: PMC8077804
• Alameer KM, Abuageelah BM, Alharbi RH, Alfaifi MH, Hurissi E, Haddad M, et al. Retrospective analysis of antibiotic resistance patterns of uropathogenic Escherichia coli with focus on extended‐spectrum β‐lactamase at a tertiary central hospital in Saudi Arabia. Health Sci Rep. 2025 Jan 23;8(1):e70378. doi:10.1002/ hsr2.70378. PMID: 39867706; PMCID: PMC11757819
• Amiri F, Safiri S, Aletaha R, Sullman MJM, Hassanzadeh K, Kolahi A-A et al. Epidemiology of urinary tract infections in the Middle East and North Africa, 1990–2021. Trop Med Health. 2025 Feb 5;53:16. doi:10.1186/s41182 025-00692-x. PMID: 39910666; PMCID: PMC11796260
• Naber KG, Wagenlehner F, Kresken M, Cheng WY, Catillon M, Duh MS et al. Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study. Sci Rep. 2023 Jul 26;13(1):12077. doi:10.1038/s41598-023-38919-8. PMID: 37495602; PMCID: PMC10372039
• Orhan Z, Kirişci Ö, Doğaner A, Altun M, Küçük B, Aral M. Antibiotic Resistance Trends in ESKAPE Pathogens Isolated at a Health Practice and Research Hospital: A Five-Year Retrospective Study. J Infect Dev Ctries. 2024 Dec 30;18(12):1899-1908. doi:10.3855/jidc.19592. PMID:39832249
• O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. Government of the United Kingdom; 2016 [cited 2021 Jun 4]. Available from: https://apo.org.au/ sites/default/files/resource-files/2016-05/apo nid63983.pdf
• World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014